It's Getting Hot In Here: CD163 and Inflammation

Jessica J. DeWitt, Ph.D.

It finally happened! The moment you've been waiting for: your manuscript was accepted for publication! You decide to take a vacation to celebrate. You deserve the break, and you haven’t taken a vacation in years. You think somewhere tropical might be nice. You pack quickly but forget one crucial item: mosquito repellant. What happens if you get malaria? Malaria is a blood disease caused by microorganisms and transmitted by mosquitos in certain parts of the world. In advanced malaria, blood cells are lysed in the human host, releasing hemoglobin from the cells1.

Hemoglobin is an intracellular protein that carries oxygen throughout the body and has toxic effects when outside the cell, because it reacts with molecules like carbon monoxide, nitrogen monoxide, and peroxide. One of the toxic effects of hemoglobin is inflammation2.

Malaria is not the only disease that results in toxic, extracellular hemoglobin. A genetic disease has a similar effect: sickle cell disease. Sickle cell disease is a condition in which red blood cells are distorted into a sickle shape. Because of their shape, the cells degrade prematurely, resulting in chronic, low levels of extracellular hemoglobin, causing inflammation3.

Hemoglobin can also cause localized inflammation and toxicity. Atherosclerosis is a disease caused by plaques deposited on the inner walls of arteries. Plaque build-up narrows the arteries, restricting blood flow. As plaque build-up advances, micro bleeding occurs, leading to an accumulation of cholesterol, hemoglobin and other red blood cell components. The accumulation of hemoglobin at the plaque build-up site is a hotspot for inflammation4.

Besides disease, treatments that are meant to be therapeutic can also result in extracellular hemoglobin. Hemoglobin-based oxygen carriers (HBOCs) are fluids intended to replace low levels of blood cells in patients such as those with sickle cell disease. Because of the high concentration of hemoglobin in HBOCs, there is also a higher concentration of shed, extracellular hemoglobin than can be managed by the body5. Blood transfusions can also contain degraded, extracellular hemoglobin, stimulating toxic effects and inflammation seen in the above diseases6.

Luckily, the body has mechanisms in place to respond to extracellular hemoglobin. Scavenger receptors bind and remove pathogen-associated molecular patterns (PAMPs). A major scavenger receptor for hemoglobin is CD163, a protein primarily expressed in white blood cells: monocytes and macrophages. Macrophages are phagocytic (cell-eating) cells which engulf and destroy their targets. With the help of CD163, they can target extracellular hemoglobin. Since CD163 targets pro-inflammatory hemoglobin, CD163 indirectly contributes to the anti-inflammatory response7.

In addition to targeting hemoglobin for macrophages, CD163 also serves as an inflammation marker. Macrophages that express high levels of CD163 protein indicate the presence of inflammation7. As macrophages express CD163, the protein is cleaved and shed into the blood. Levels of shed CD163 in blood plasma are increased in diseases like the ones described. Keeping track of CD163 could be a way to monitor the bodies response to extracellular hemoglobin and disease progression. CD163 could also be used as a marker for targeting hemoglobin for therapeutic intervention8.

Bethyl's CD163 Recombinant Monoclonal Antibody is perfect for your research needs.

Detection of human CD163 in FFPE liver carcinoma by IHC.

Detection of human CD163 in FFPE liver carcinoma by IHC. Antibody: Rabbit anti-CD163 recombinant monoclonal [BLR087G] (A700-087). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Substrate: DAB.

Detection of human CD163 in FFPE lung carcinoma by IHC.

Detection of human CD163 in FFPE lung carcinoma by IHC. Antibody: Rabbit anti-CD163 recombinant monoclonal [BLR087G] (A700-087). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Substrate: DAB.

Detection of human CD163 in FFPE lung carcinoma pleural fluid by IHC.

Detection of human CD163 in FFPE lung carcinoma pleural fluid by IHC. Antibody: Rabbit anti-CD163 recombinant monoclonal [BLR087G] (A700-087). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Substrate: DAB.


References

1. White NJ. 2018. Anaemia and malaria. Malaria journal. 17(1): 371-371.

2. Schaer DJ and Buehler PW. 2013. Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies. Cold Spring Harbor perspectives in medicine. 3(6): a013433.

3. Kato GJ, Steinberg MH and Gladwin MT. 2017. Intravascular hemolysis and the pathophysiology of sickle cell disease. The Journal of clinical investigation. 127(3): 750-760.

4. Guo L, Akahori H, Harari E, Smith SL, Polavarapu R, Karmali V, Otsuka F, Gannon RL, Braumann RE, Dickinson MH, Gupta A, Jenkins AL, Lipinski MJ, Kim J, Chhour P, de Vries PS, Jinnouchi H, Kutys R, Mori H, Kutyna MD, Torii S, Sakamoto A, Choi CU, Cheng Q, Grove ML, Sawan MA, Zhang Y, Cao Y, Kolodgie FD, Cormode DP, Arking DE, Boerwinkle E, Morrison AC, Erdmann J, Sotoodehnia N, Virmani R and Finn AV. 2018. CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis. The Journal of clinical investigation. 128(3): 1106-1124.

5. Buehler PW, D'Agnillo F and Schaer DJ. 2010. Hemoglobin-based oxygen carriers: From mechanisms of toxicity and clearance to rational drug design. Trends in molecular medicine. 16(10): 447-457.

6. Goubran H, Sheridan D, Radosevic J, Burnouf T and Seghatchian J. 2017. Transfusion-related immunomodulation and cancer. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 56(3): 336-340.

7. Garton T, Keep RF, Hua Y and Xi G. 2017. CD163, a Hemoglobin/Haptoglobin Scavenger Receptor, After Intracerebral Hemorrhage: Functions in Microglia/Macrophages Versus Neurons. Translational stroke research. 8(6): 612-616.

8. Immenschuh S, Vijayan V, Janciauskiene S and Gueler F. 2017. Heme as a Target for Therapeutic Interventions. Frontiers in pharmacology. 8: 146-146.